DIA Biosimilars 2013

Bracket

Parthenon Capital acquires Bracket

Friday, August 16, 2013 10:15 AM

Bracket, a specialty services provider, has been acquired by Parthenon Capital Partners, a growth-oriented private equity firm based in Boston and San Francisco, from Express Scripts Holding Company.

More... »

Cenduit: Now with Patient Reminders

Bracket joins ePRO Consortium, program of Critical Path Institute

Friday, March 2, 2012 07:07 AM

Bracket, a division of UBC, has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, which seeks to improve the quality of patient reported outcomes, a crucial element in the drug development process.

More... »

CRF Health – eCOA Forum

UBC’s new Bracket division makes Texas ePRO company Arrowhead its first acquisition

Monday, July 18, 2011 08:00 AM

Bracket, a division of United BioSource Corp. (UBC) established just last month, has made its first acquisition: Arrowhead Electronic Healthcare, a privately-held, Austin, Texas-based electronic patient-reported outcome (ePRO) technologies company. The terms were not disclosed.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs